Industry verticals
Warm Introductions in Biotech and Pharmaceutical Business Development
Pharmaceutical licensing is the most relationship-governed deal market in B2B: 516 transactions worth more than $250 billion in 2025, nearly all sourced through bankers, shared investors, and the structured conference circuit rather than cold outreach.
Pharmaceutical licensing deals outnumber pharma acquisitions by approximately 10:1. For every company bought outright, roughly ten asset licensing or collaboration agreements are signed. IQVIA's 2025 Pharma Deals Annual Review counted 516 licensing transactions worth more than $250 billion globally, with deal activity accelerating across oncology, immunology, and rare disease following improved biomarker validation tools that made earlier-stage asset partnerships commercially viable. BioCentury Deals Analytics recorded a 42% year-on-year increase in pre-clinical collaboration agreements in 2024 alone.
None of those deals was sourced through cold email. The pharma corporate development teams that closed those transactions (the groups at AstraZeneca, Pfizer, Roche, Novartis, and their peers that are actively in-licensing assets) receive hundreds of cold approaches monthly and evaluate almost none of them. The structural reason is not that the cold approaches describe poor assets; it is that a cold approach communicates nothing about asset quality, management credibility, or fit with the pharma company's therapeutic-area priorities that the BD team can act on. What converts in pharmaceutical licensing is the introduction that arrives through a trusted relationship: a banker who knows both parties, a shared investor who holds relationships on both sides of the deal, or a CRO partner whose operational experience with the biotech provides the due-diligence signal a cold email cannot.
The introduction channels that define pharma licensing deal flow
The healthcare conference circuit as deal-introduction infrastructure
Pharmaceutical licensing is not sourced through cold outreach; it is sourced through the structured partnering calendar that forms around a handful of annual conferences, above all the J.P. Morgan Healthcare Conference and BIO International Convention. The J.P. Morgan Healthcare Conference draws 8,000+ senior executives from 40+ countries and more than 500 companies; it is the most concentrated gathering of pharma corporate development teams and biotech CEOs of the year. The BIO International Convention operates the BIO ONE-ON-ONE Partnering system, which facilitates tens of thousands of formal bilateral partnering meetings annually. Neither venue is a spontaneous-conversation conference: by the time executives arrive in San Francisco in January, the meeting calendars are already full, booked weeks or months in advance through existing relationships and banker introductions. The pharmaceutical BD head who receives a cold introduction request during the conference itself is almost certainly already scheduled through the day; the introductions that secure those slots come from investment bankers who have pre-sold both parties on the strategic fit, from shared investors who hold relationships with both the biotech’s management and the pharma’s corporate development team, or from CRO and CDMO account managers who serve both organizations. The conference functions as the meeting venue, not the sourcing mechanism. Sourcing happens through the relationships that filled the calendar before anyone boarded a plane. For biotech companies and pharma BD teams seeking to use the conference circuit effectively, the prerequisite is the relationship infrastructure that gets them into the bilateral meeting system before the conference opens, not the conference floor itself.
Investment banks and life sciences advisors as deal-flow connectors
Pharmaceutical licensing deals outnumber pharma M&A transactions by approximately 10:1 (for every acquisition, roughly ten licensing agreements occur), which makes licensing the dominant category of healthcare investment banking by transaction volume. Specialized life sciences investment banks (Jefferies, Leerink Partners, Evercore ISI healthcare, SVB Securities, Guggenheim Life Sciences) and the healthcare groups at major investment banks (J.P. Morgan, Goldman Sachs, Morgan Stanley) maintain active, bilateral relationships with pharma corporate development teams and biotech CEOs simultaneously. They function explicitly as deal-flow connectors: when a biotech’s asset profile matches what a pharma BD team is actively in-licensing, the banker who knows both parties can make an introduction that arrives pre-qualified. The banker’s institutional reputation is attached to the quality of the introductions they facilitate: a banker who brings poor-fit deals loses credibility on both sides of the market, which means banker introductions carry an implicit due-diligence signal that cold outreach cannot replicate. IQVIA data shows that pharma licensing deal volume reached 516 transactions in 2025, valued at more than $250 billion, with the deal structure evolution toward option-based and milestone-heavy agreements accelerating the role of financial advisors who understand how to price and structure risk-sharing terms. BioCentury Deals Analytics noted a 42% year-on-year increase in pre-clinical collaboration agreements in 2024, as earlier-stage deals attracted more licensing interest following improved biomarker validation tools, driving demand for the relationship access that bankers provide at the pre-clinical and phase 1 stages where cold BD contact is least likely to land.
The CRO and CDMO network as a cross-industry connector layer
Contract research organizations and contract development and manufacturing organizations occupy an unusual position in the pharmaceutical ecosystem: they serve both small biotech clients and large pharma clients simultaneously, often on the same therapeutic areas and sometimes in adjacent program phases. A CRO running phase 2 clinical trials for a mid-size biotech may also be running phase 3 trials for the pharma company that is the most natural licensing partner for that biotech’s asset. The CRO account manager and medical science liaison who hold relationships with both sides are in a position to facilitate introductions that would be structurally unavailable through direct cold outreach. This cross-industry connector role is not formalized (CROs are not deal brokers and do not charge introduction fees), but it operates as an informal trust-transfer mechanism through the shared institutional context that CRO and CDMO relationships create. A biotech BD head who has worked closely with a CRO’s clinical team over a multi-year trial will trust that team’s judgment about which pharma counterparts are worth talking to; the CRO’s recommendation arrives with the operational credibility of a multi-year collaboration rather than the commercial interest of a placement fee. Deloitte’s 2025 life sciences transformation report found that 63% of new pharmaceutical partnerships now include shared development responsibilities, up from 38% in 2021, which increases the role of intermediaries who understand both parties’ operational capacity and can make introductions calibrated to the actual feasibility of a co-development relationship, not just a theoretical licensing fit.
What makes a pharma licensing introduction brief work
Lead with asset specificity, not company narrative
A pharma BD introduction brief that leads with company history, platform technology descriptions, or general capability statements gives the connector nothing actionable. The pharma corporate development team that the connector is introducing the biotech to already receives hundreds of similar company-level pitches; what they evaluate is asset specificity: the mechanism of action, the indication, the stage of development, the primary endpoint data, and the differentiation from existing approved or in-development therapies in the same therapeutic area or indication. A brief for a licensing introduction must be written at the asset level, not the company level. The connector, whether a banker, a CRO account manager, or a shared investor, needs to be able to forward a description that the pharma BD head can evaluate in two minutes and determine whether the asset profile matches what they are actively seeking. That description must include the scientific rationale for the asset in the clinical indication, the development stage and primary endpoint readiness, the competitive landscape and differentiation argument, and an honest characterization of what the biotech is seeking in a licensing partner: upfront capital, co-development resource, or geographic rights split. Connectors who forward vague asset descriptions lose credibility with the pharma contacts they introduce to; a connector who forwards an asset-specific brief that matches the pharma’s stated therapeutic-area priorities is doing work that the pharma BD team values and will attribute to the connector relationship.
Sequence introductions to match the deal timeline
Pharmaceutical licensing introductions are not single-touch events. They initiate relationships that develop across months or years before a term sheet is signed, if one is signed at all. The timing of the introduction relative to the asset’s development stage, the pharma company’s in-licensing priorities, and the competitive process matters more in pharma licensing than in most B2B contexts. An introduction made 12 months before phase 2 data readout, when the pharma company has already committed budget to a competing asset, will not convert regardless of relationship quality. An introduction made six months before a data readout, when the pharma company is building its option portfolio for potential in-licensing post-data, may initiate a relationship that is ready to act the moment the data lands. The most effective pharma BD teams map their introduction sequencing against their program timelines: they identify which pharma companies are the natural licensing partners for each asset in each indication, determine when those partners are likely to be actively evaluating in-licensing opportunities in that space (often driven by their own pipeline gaps and loss-of-exclusivity calendars), and time the connector introduction to arrive when the pharma BD team is in active evaluation mode rather than committed or closed. Investment bankers are most valuable in this sequencing role: they maintain real-time visibility into which pharma companies are actively seeking in-licensing in which therapeutic areas, which is why the banker introduction lands more effectively than the direct approach even when the biotech has a direct contact at the pharma company.
FAQ
FAQs on biotech and pharma BD introductions
Why is cold outreach so ineffective in pharmaceutical licensing?
Pharmaceutical corporate development teams at large pharma companies receive hundreds of unsolicited licensing approaches each month, more than any team can evaluate. The structural filter that determines which approaches get evaluated is not the quality of the asset (which the BD team cannot assess from a cold email) but the quality of the introduction: who sent it and what that person knows about both parties. A cold approach from an unknown biotech CEO signals only that the company has a BD team and a licensing interest; it does not signal asset quality, management credibility, or strategic fit with the pharma company’s therapeutic-area priorities. A banker introduction signals that a financial professional who understands pharma deal terms and has evaluated the asset believes it warrants the pharma BD team’s time. A CRO introduction signals that an organization with direct operational knowledge of the biotech’s clinical execution believes the relationship is worth exploring. The information content of the introduction is what matters. Cold outreach communicates almost none of it.
How does the BIO ONE-ON-ONE Partnering system work?
The BIO International Convention’s ONE-ON-ONE Partnering system is a structured bilateral meeting platform that allows attendees to request meetings with other registered organizations before the conference. Both parties must accept the meeting request for it to be scheduled; the system then generates a calendar of confirmed meetings across the conference days. The key constraint is that meeting slots fill up in the weeks before the conference: attendees who arrive without a pre-filled calendar have limited opportunities to secure meetings with the most in-demand pharma BD teams. The introductions that secure those meeting slots typically come through existing relationships: a shared investor who can facilitate a mutual introduction through the system, a banker who has confirmed both parties’ interest before the conference and is managing the introduction, or a prior relationship from earlier in a company’s development. For biotech companies attending BIO for the first time, the conference is most valuable as a venue to build the relationships that will secure future meeting slots, not as a mechanism for generating immediate licensing discussions from cold starting positions.
What role do shared investors play in pharmaceutical licensing introductions?
Life sciences venture capital firms and crossover investors often hold positions in multiple biotech companies across different therapeutic areas simultaneously, and they maintain relationships with the pharma corporate development teams who are natural licensing partners for their portfolio companies. A VC partner who has co-invested with a pharma company’s corporate VC arm (such as Pfizer Ventures, Merck Global Health Innovation Fund, or Novartis Venture Fund) holds a bilateral trust relationship that is particularly effective for licensing introductions: the pharma corporate VC relationship means the introduction arrives through a financial relationship rather than a purely commercial sales context. Shared investor introductions are most effective when the investor can honestly characterize the fit (they know both the biotech’s asset quality and the pharma company’s therapeutic priorities) and when the biotech has a relationship with the investor deep enough for the investor to commit their own credibility to the introduction. Investors who make introductions to licensing partners they believe in tend to do it proactively, without being asked, when the fit is clear; biotechs seeking introductions from their investors are most likely to succeed when the asset profile genuinely matches what the investor knows the pharma company is seeking.
How do CRO relationships translate into licensing introductions?
A CRO account relationship becomes an introduction asset when it is deep enough that the CRO contact can honestly characterize the biotech’s management quality, clinical execution, and asset credibility to a pharma contact they know. This requires a relationship that goes beyond transactional service delivery: the CRO account manager or therapeutic area director who has been embedded in a biotech’s clinical program for 18 months knows the management team, the data quality, the regulatory communication, and the operational discipline of the company in ways that a two-year-old company in cold outreach mode cannot credibly convey on its own. Not all CRO relationships reach this depth: transactional relationships with multiple service providers spread across different CROs rarely generate the trust needed for a credible cross-firm introduction. Biotech companies that concentrate CRO relationships and invest in genuine partnership-level collaboration with one or two key CRO partners tend to build the relationship depth that generates informal introduction opportunities; those that view CROs as interchangeable service vendors rarely get there. The CDMO relationship follows the same dynamic: a manufacturing partner who knows a biotech’s formulation, manufacturing scalability, and supply chain infrastructure is in a position to make introductions to pharma companies evaluating co-development agreements that include manufacturing commitments, a structurally valuable introduction type that requires genuine manufacturing relationship depth.
How does LetsBridge support biotech companies and pharma BD teams seeking licensing introductions?
LetsBridge helps biotech companies identify connectors with genuine, trusted relationships to pharma corporate development contacts: investors with bilateral pharma relationships, CRO and CDMO account managers who have worked across both sides of a potential licensing relationship, and advisors who know the therapeutic-area priorities of specific pharma BD teams well enough to facilitate a credible introduction. Rather than mapping the full network to find any connection to a pharma company, the platform identifies connectors whose relationships carry the trust content that makes a pharma licensing introduction land: direct knowledge of both the asset and the pharma company’s in-licensing priorities. For pharma BD teams seeking to identify early-stage biotech assets through relationship channels rather than cold inbound, the platform connects them with the investors, advisors, and scientific community members who have direct knowledge of pre-publication programs, the assets that are not yet appearing in conference presentations but are approaching the stage where licensing discussions are relevant.
Reach pharma BD teams through the relationships that matter
Connect with the bankers, shared investors, and CRO partners whose introductions carry the credibility that pharmaceutical corporate development teams require.